KALV

+ Watchlist + Portfolio

KalVista Pharmaceuticals, Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.00
52-Week Range: $9.83 – $27.00
Market Cap: $1.44B
P/E (TTM): —
EPS (TTM): -3.94
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: —
Gross Margin: 51.07%
Operating Margin: -57.37%
Profit Margin: -118.74%
Current Ratio: 5.17
Debt/Equity: —
Total Debt: $284.31M
Free Cash Flow: —
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $1.44B

KALV Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$70.17M	$80.28M	$86.17M	$71.71M
Selling, General & Admin	$26.45M	$30.59M	$54.28M	$116.29M
Operating Expenses	$81.31M	$95.09M	$131.99M	$182.98M
Operating Income	-$81.31M	-$95.09M	-$131.99M	-$182.98M
EBITDA	-$80.75M	-$94.37M	-$125.83M	-$173.33M
Pretax Income	-$82.34M	-$92.91M	-$126.64M	-$180.05M
Income Tax	$0.00	$0.00	$0.00	$3.39M
Net Income	-$82.34M	-$92.91M	-$126.64M	-$183.44M
Diluted EPS	-3.36	-3.33	-3.44	-3.69
Diluted Shares	24.47M	27.89M	36.79M	49.65M

KALV Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$56.24M	$31.79M	$131.62M	$229.34M
Receivables	$18.64M	$10.87M	$15.14M	$11.30M
Inventory	—	$0.00	$0.00	$3.43M
Current Assets	$172.33M	$225.69M	$241.69M	$320.15M
Total Assets	$183.20M	$235.40M	$250.77M	$335.38M
Current Liabilities	$15.03M	$22.81M	$45.17M	$57.35M
Long-Term Debt	—	—	—	$139.23M
Total Debt	$8.23M	$7.32M	$6.31M	$151.57M
Total Liabilities	$22.18M	$28.82M	$155.38M	$338.09M
Retained Earnings	-$343.08M	-$469.73M	-$653.17M	-$762.69M
Shareholders' Equity	$161.03M	$206.58M	$95.39M	-$2.71M
Working Capital	$157.29M	$202.88M	$196.52M	$262.79M

KALV Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$78.13M	-$75.26M	-$89.23M	-$152.91M
Capital Expenditure	-$931.00K	-$1.20M	-$443.00K	-$929.00K
Free Cash Flow	-$79.06M	-$76.46M	-$89.67M	-$153.84M
Depreciation & Amortisation	$564.00K	$718.00K	$816.00K	$941.00K
Stock-Based Compensation	$11.09M	$9.92M	$21.91M	$12.29M
Investing Cash Flow	$57.86M	$41.41M	-$84.72M	$91.02M
Financing Cash Flow	$1.58M	$58.12M	$150.71M	$159.73M
Net Change in Cash	-$18.69M	$24.27M	-$23.24M	$97.84M

KALV Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q3 2025	Q1 2026
Revenue	$0.00	$0.00	$1.43M	$13.69M	$40.86M
Cost of Revenue	—	—	$590.00K	$1.23M	$3.09M
Gross Profit	—	—	$836.00K	$12.46M	$37.77M
Research & Development	$12.59M	$15.89M	$15.16M	$11.99M	$12.42M
Selling, General & Admin	$30.35M	$39.14M	$44.68M	$46.52M	$48.80M
Operating Expenses	$42.94M	$50.02M	$59.84M	$58.51M	$61.22M
Operating Income	-$42.94M	-$50.02M	-$59.01M	-$46.05M	-$23.44M
EBITDA	-$41.19M	-$49.88M	-$54.16M	-$42.57M	-$17.55M
Pretax Income	-$44.26M	-$53.08M	-$57.94M	-$47.33M	-$23.49M
Income Tax	$4.25M	-$855.00K	$2.16M	$2.16M	$0.00
Net Income	-$48.51M	-$52.23M	-$60.10M	-$49.48M	-$23.49M
Diluted EPS	-0.92	—	-1.12	-0.92	-0.43
Diluted Shares	52.64M	—	53.50M	53.88M	54.58M

KALV Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q3 2025	Q1 2026
Cash & Equivalents	$167.29M	$131.62M	$124.30M	$243.50M	$213.77M
Receivables	$9.40M	$15.14M	$6.50M	$7.12M	$17.33M
Inventory	—	$0.00	—	$458.00K	$4.00M
Current Assets	$267.36M	$241.69M	$205.90M	$325.23M	$314.20M
Total Assets	$275.99M	$250.77M	$215.50M	$339.93M	$328.92M
Current Liabilities	$25.61M	$45.17M	$38.38M	$45.07M	$60.82M
Long-Term Debt	—	—	—	$139.03M	$139.40M
Total Debt	$5.78M	$6.31M	$6.14M	$149.59M	$151.50M
Total Liabilities	$130.87M	$155.38M	$174.72M	$322.93M	$348.57M
Retained Earnings	-$600.95M	-$653.17M	-$713.27M	-$739.10M	-$786.18M
Shareholders' Equity	$145.13M	$95.39M	$40.79M	$17.00M	-$19.65M
Working Capital	$241.74M	$196.52M	$167.52M	$280.16M	$253.39M

Market Snapshot

About

KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing small molecule protease inhibitors. The company's primary focus is on developing oral treatments for hereditary angioedema (HAE), a rare genetic disorder causing painful and potentially life-threatening swelling attacks. KalVista's pipeline includes both on-demand and prophylactic therapies targeting plasma kallikrein, a key enzyme in the HAE disease pathway. The company is advancing multiple clinical-stage programs aimed at providing more convenient treatment options for HAE patients.